EMA Authorised: MabThera (rituximab) — Roche Registration GmbH

View source ↗

Summary

EMA authorised MabThera (rituximab) for multiple indications including Non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Roche Registration GmbH. Decision date: 03/04/2025